CA3114021C - METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE - Google Patents

METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE

Info

Publication number
CA3114021C
CA3114021C CA3114021A CA3114021A CA3114021C CA 3114021 C CA3114021 C CA 3114021C CA 3114021 A CA3114021 A CA 3114021A CA 3114021 A CA3114021 A CA 3114021A CA 3114021 C CA3114021 C CA 3114021C
Authority
CA
Canada
Prior art keywords
beta
hydroxypropyl
cyclodextrin
cyclodextrin composition
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3114021A
Other languages
English (en)
French (fr)
Other versions
CA3114021A1 (en
Inventor
Sharon H. Hrynkow
Jeffrey L. Tate
Scott Fine N.
Original Assignee
Cyclo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclo Therapeutics Inc filed Critical Cyclo Therapeutics Inc
Publication of CA3114021A1 publication Critical patent/CA3114021A1/en
Application granted granted Critical
Publication of CA3114021C publication Critical patent/CA3114021C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA3114021A 2018-10-29 2019-10-24 METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE Active CA3114021C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862752131P 2018-10-29 2018-10-29
US62/752,131 2018-10-29
US201962885053P 2019-08-09 2019-08-09
US62/885,053 2019-08-09
PCT/US2019/057784 WO2020092107A1 (en) 2018-10-29 2019-10-24 Methods for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
CA3114021A1 CA3114021A1 (en) 2021-05-07
CA3114021C true CA3114021C (en) 2025-05-27

Family

ID=68583503

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3114021A Active CA3114021C (en) 2018-10-29 2019-10-24 METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE

Country Status (10)

Country Link
US (3) US11925659B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873604B1 (cg-RX-API-DMAC7.html)
JP (1) JP7446322B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210084480A (cg-RX-API-DMAC7.html)
CN (1) CN112996562A (cg-RX-API-DMAC7.html)
BR (1) BR112021008139A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114021C (cg-RX-API-DMAC7.html)
ES (1) ES2992137T3 (cg-RX-API-DMAC7.html)
PT (1) PT3873604T (cg-RX-API-DMAC7.html)
WO (1) WO2020092107A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US11466008B2 (en) 2017-09-18 2022-10-11 Eip Pharma, Llc Co-crystals of neflamapimod (VX-745)
AU2020204925B2 (en) 2019-01-03 2025-11-20 Cyclarity Therapeutics, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
AU2021284155A1 (en) * 2020-06-02 2023-01-05 National University Of Singapore Compositions, their uses in therapy and methods thereof
WO2022051631A1 (en) 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
CA3200988A1 (en) * 2020-11-06 2022-05-12 John Jahangir Alam Treatment of gait dysfunction in neurodegenerative disease
WO2022099094A1 (en) * 2020-11-06 2022-05-12 Eip Pharma, Inc. Compositions and methods for treating depression
WO2022197640A1 (en) * 2021-03-14 2022-09-22 Massachusetts Institute Of Technology Apoe4 impairs myelination via altered cholesterol biosynthesis and transport in neuronal cells
EP4433828A1 (en) * 2021-11-18 2024-09-25 Vib Vzw Improved gamma-secretase inhibitor screening assays
JP2025506676A (ja) 2022-02-18 2025-03-13 ベレン セラピューティクス ピー.ビー.シー. ヒドロキシプロピル-ベータ-シクロデキストリンの組成物及びその精製方法
WO2023191425A1 (ko) * 2022-03-28 2023-10-05 주식회사 비엔에이치리서치 약물의 전기생리학적 스크리닝 방법
CN114569742B (zh) * 2022-05-09 2022-07-19 北京剂泰医药科技有限公司 一种组合物及其制备方法和应用
KR20250024808A (ko) * 2022-06-13 2025-02-19 베렌 테라퓨틱스 피.비.씨. 하이드록시프로필-베타-사이클로덱스트린 제조를 위한 시스템 및 방법
CA3263540A1 (en) * 2022-07-29 2024-02-01 Anavex Life Sciences Corp. Compositions and methods for the prevention of cognitive decline caused by degenerative diseases
US20260124236A1 (en) * 2022-09-30 2026-05-07 Cyclo Therapeutics, Inc. Methods for treating early alzheimer’s disease
WO2025214478A1 (zh) * 2024-04-12 2025-10-16 北京华昊中天生物医药股份有限公司 一种优替德隆药物组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5569756A (en) 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
US8883494B2 (en) 2003-11-14 2014-11-11 Adil A. KHAN In vitro model for neuronal death
KR101530050B1 (ko) 2007-03-02 2015-06-22 주식회사 노브메타파마 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법
WO2013155485A2 (en) 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin
CA2880880C (en) 2012-08-03 2021-01-26 John Mckew Cyclodextrin for the treatment of lysosomal storage diseases
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
KR20170012555A (ko) * 2014-06-12 2017-02-02 더 유니버시티 오브 노트르 담 듀락 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법
WO2016168772A1 (en) 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
EP3432880A4 (en) * 2016-03-20 2019-12-11 Asdera LLC USE OF CYCLODEXTRINS TO REDUCE ENDOCYTOSIS IN MALIGNES AND NEURODEEGENERATIVE DISEASES

Also Published As

Publication number Publication date
ES2992137T3 (es) 2024-12-09
US20240415871A1 (en) 2024-12-19
EP3873604A1 (en) 2021-09-08
US11925659B2 (en) 2024-03-12
BR112021008139A2 (pt) 2021-08-03
JP7446322B2 (ja) 2024-03-08
CA3114021A1 (en) 2021-05-07
JP2022509358A (ja) 2022-01-20
EP3873604B1 (en) 2024-08-21
WO2020092107A1 (en) 2020-05-07
PT3873604T (pt) 2024-10-22
US20220008453A1 (en) 2022-01-13
KR20210084480A (ko) 2021-07-07
CN112996562A (zh) 2021-06-18
US20250302864A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
US11925659B2 (en) Methods for treating Alzheimer's disease
US20250114330A1 (en) (3ar)-1,3a,8-trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
HK1242998A1 (zh) 治疗法布里病的给药方案
CA2988529A1 (en) Hydroxypropyl beta-cyclodextrin compositions and methods
KR20150002681A (ko) App 특이적 bace 억제제(asbi) 및 이의 용도
Rainov et al. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?
EP3445369B1 (en) Vx-745 for use in the treatment of dementia
TW202425995A (zh) 減少與神經退化疾病相關的神經退化的方法
WO2024073409A1 (en) Methods for treating early alzheimer's disease
HK40059055B (en) Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin
HK40059055A (en) Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin
Budhwani et al. Exosome-mediated delivery of a PLD1 modulator overcomes bioavailability hurdles to target synaptopathy in neurodegenerative diseases
CA3268619A1 (en) Methods for treating early alzheimer's disease
WO2015198329A1 (en) Injectable formulations for intrathecal administration of antibiotic agents
NZ615726B2 (en) Dosing regimens for the treatment of fabry disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220923

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241018

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241018

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241018

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250306

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250306

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250306

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20250327

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250425

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250425

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250521

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250527

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251017